Diabetic Nephropathy - Pipeline Review, H2 2018

Diabetic Nephropathy - Pipeline Review, H2 2018


  • Products Id :- GMDHC10727IDB
  • |
  • Pages: 245
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Diabetic Nephropathy-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy-Pipeline Review, H2 2018, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 18, 13, 26 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 4

Diabetic Nephropathy-Overview 5

Diabetic Nephropathy-Therapeutics Development 6

Diabetic Nephropathy-Therapeutics Assessment 17

Diabetic Nephropathy-Companies Involved in Therapeutics Development 27

Diabetic Nephropathy-Drug Profiles 46

Diabetic Nephropathy-Dormant Projects 220

Diabetic Nephropathy-Discontinued Products 224

Diabetic Nephropathy-Product Development Milestones 226

Appendix 236

List of Figures

Number of Products under Development for Diabetic Nephropathy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

List of Tables

Number of Products under Development for Diabetic Nephropathy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Diabetic Nephropathy-Pipeline by Antisense Therapeutics Ltd, H2 2018

Diabetic Nephropathy-Pipeline by Araim Pharmaceuticals Inc, H2 2018

Diabetic Nephropathy-Pipeline by Astellas Pharma Inc, H2 2018

Diabetic Nephropathy-Pipeline by AstraZeneca Plc, H2 2018

Diabetic Nephropathy-Pipeline by Bayer AG, H2 2018

Diabetic Nephropathy-Pipeline by BLR Bio LLC, H2 2018

Diabetic Nephropathy-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Diabetic Nephropathy-Pipeline by Cellmid Ltd, H2 2018

Diabetic Nephropathy-Pipeline by ChemoCentryx Inc, H2 2018

Diabetic Nephropathy-Pipeline by CSL Ltd, H2 2018

Diabetic Nephropathy-Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Diabetic Nephropathy-Pipeline by DiaMedica Therapeutics Inc, H2 2018

Diabetic Nephropathy-Pipeline by Dimerix Bioscience Pty Ltd, H2 2018

Diabetic Nephropathy-Pipeline by GenKyoTex SA, H2 2018

Diabetic Nephropathy-Pipeline by Gilead Sciences Inc, H2 2018

Diabetic Nephropathy-Pipeline by GNI Group Ltd, H2 2018

Diabetic Nephropathy-Pipeline by Inspyr Therapeutics Inc, H2 2018

Diabetic Nephropathy-Pipeline by Ironwood Pharmaceuticals Inc, H2 2018

Diabetic Nephropathy-Pipeline by Johnson & Johnson, H2 2018

Diabetic Nephropathy-Pipeline by MediPost Co Ltd, H2 2018

Diabetic Nephropathy-Pipeline by Merck & Co Inc, H2 2018

Diabetic Nephropathy-Pipeline by Mesoblast Ltd, H2 2018

Diabetic Nephropathy-Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018

Diabetic Nephropathy-Pipeline by Novo Nordisk AS, H2 2018

Diabetic Nephropathy-Pipeline by Noxxon Pharma AG, H2 2018

Diabetic Nephropathy-Pipeline by Paranta Biosciences Ltd, H2 2018

Diabetic Nephropathy-Pipeline by PhytoHealth Corp, H2 2018

Diabetic Nephropathy-Pipeline by ProMetic Life Sciences Inc, H2 2018

Diabetic Nephropathy-Pipeline by Reata Pharmaceuticals Inc, H2 2018

Diabetic Nephropathy-Pipeline by Redx Pharma Plc, H2 2018

Diabetic Nephropathy-Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Diabetic Nephropathy-Pipeline by Sarfez Pharmaceuticals Inc, H2 2018

Diabetic Nephropathy-Pipeline by Serodus ASA, H2 2018

Diabetic Nephropathy-Pipeline by Teijin Pharma Ltd, H2 2018

Diabetic Nephropathy-Pipeline by Theravance Biopharma Inc, H2 2018

Diabetic Nephropathy-Pipeline by Twoxar Inc, H2 2018

Diabetic Nephropathy-Pipeline by Ube Industries Ltd, H2 2018

Diabetic Nephropathy-Pipeline by Vascular Pharmaceuticals Inc, H2 2018

Diabetic Nephropathy-Pipeline by Vicore Pharma AB, H2 2018

Diabetic Nephropathy-Dormant Projects, H2 2018

Diabetic Nephropathy-Dormant Projects, H2 2018 (Contd..1), H2 2018

Diabetic Nephropathy-Dormant Projects, H2 2018 (Contd..2), H2 2018

Diabetic Nephropathy-Dormant Projects, H2 2018 (Contd..3), H2 2018

Diabetic Nephropathy-Discontinued Products, H2 2018

Diabetic Nephropathy-Discontinued Products, H2 2018 (Contd..1), H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Antisense Therapeutics Ltd

Araim Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Bayer AG

BLR Bio LLC

Boehringer Ingelheim GmbH

Cellmid Ltd

ChemoCentryx Inc

CSL Ltd

Daiichi Sankyo Co Ltd

DiaMedica Therapeutics Inc

Dimerix Bioscience Pty Ltd

GenKyoTex SA

Gilead Sciences Inc

GNI Group Ltd

Inspyr Therapeutics Inc

Ironwood Pharmaceuticals Inc

Johnson & Johnson

MediPost Co Ltd

Merck & Co Inc

Mesoblast Ltd

Mitsubishi Tanabe Pharma Corp

Novo Nordisk AS

Noxxon Pharma AG

Paranta Biosciences Ltd

PhytoHealth Corp

ProMetic Life Sciences Inc

Reata Pharmaceuticals Inc

Redx Pharma Plc

Regeneron Pharmaceuticals Inc

Sarfez Pharmaceuticals Inc

Serodus ASA

Teijin Pharma Ltd

Theravance Biopharma Inc

Twoxar Inc

Ube Industries Ltd

Vascular Pharmaceuticals Inc

Vicore Pharma AB

Diabetic Nephropathy Therapeutic Products under Development, Key Players in Diabetic Nephropathy Therapeutics, Diabetic Nephropathy Pipeline Overview, Diabetic Nephropathy Pipeline, Diabetic Nephropathy Pipeline Assessment

select a license
Single User License
USD 2000 INR 138340
Site License
USD 4000 INR 276680
Corporate User License
USD 6000 INR 415020

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com